PORT-3 / AlphaTON Capital - LARVOL DELTA

PRECIOUS-01: Dose Escalation Study of Immunomodulatory Nanoparticles (clinicaltrials.gov) - P1 | N=15 | Active, not recruiting | Sponsor: Radboud University Medical Center | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Jul 2025 ➔ Dec 2026

First-in-human • Trial completion date • Trial primary completion date • Esophageal Squamous Cell Carcinoma • Oncology • Solid Tumor • CTAG1B

PRECIOUS-01: Dose Escalation Study of Immunomodulatory Nanoparticles (clinicaltrials.gov) - P1 | N=15 | Active, not recruiting | Sponsor: Radboud University Medical Center | Recruiting ➔ Active, not recruiting | Trial completion date: Jul 2025 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Jul 2025

Enrollment closed • Trial completion date • Trial primary completion date • Esophageal Squamous Cell Carcinoma • Oncology • Solid Tumor • CTAG1B

PRECIOUS-01: Dose Escalation Study of Immunomodulatory Nanoparticles (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: Radboud University Medical Center | Trial completion date: Jul 2024 ➔ Jul 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Immunomodulating • Trial completion date • Trial primary completion date • Esophageal Squamous Cell Carcinoma • Oncology • Solid Tumor • CD20 • CD8 • CTAG1B • FOXP3

PRECIOUS-01: Dose Escalation Study of Immunomodulatory Nanoparticles (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: Radboud University Medical Center | Trial completion date: Dec 2023 ➔ Jul 2024 | Trial primary completion date: Sep 2023 ➔ Dec 2023

Immunomodulating • Trial completion date • Trial primary completion date • Esophageal Squamous Cell Carcinoma • Immune Modulation • Oncology • Solid Tumor • CD20 • CD8 • CTAG1B • FOXP3

PRECIOUS-01: Dose Escalation Study of Immunomodulatory Nanoparticles (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: Radboud University Medical Center | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Sep 2022 ➔ Sep 2023

Trial completion date • Trial primary completion date • Esophageal Squamous Cell Carcinoma • Immune Modulation • Inflammation • Oncology • Solid Tumor • CD20 • CD8 • CTAG1B • FOXP3

Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform (GlobeNewswire) - "Portage now holds 100% ownership of iOx Therapeutics Ltd...Portage Biotech Inc announced that the Company has acquired the outstanding ownership interest (approximately 22%) of its invariant natural killer T cell (iNKT agonist) platform and now fully owns the worldwide rights to its small molecule iNKT agonists, including lead programs PORT-2 and PORT-3...Additionally, a payment of $25,000,000 in Portage ordinary shares or cash would be triggered upon the achievement of a certain clinical milestone in the PORT-2 or PORT-3 programs....Both PORT-2 and PORT-3 are in clinical trials in melanoma and non-small cell lung cancer (PORT-2) and NY-ESO-1 positive solid tumors (PORT-3). The Company expects preliminary data from these programs by the end of 2022 and early 2023, respectively."

Clinical data • Commercial • M&A • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year (GlobeNewswire) - "The IMP-MEL study is part of a comprehensive clinical development plan to evaluate Portage’s iNKT agonist therapies, PORT-2 and PORT-3. PORT-3 is currently being evaluated in a Phase 1 clinical trial initiated in April 2021....The trials are being conducted in Europe and the UK with delays in enrollment due to the ongoing COVID-19 pandemic. Initial safety results are expected in January 2022."

P1 data • Trial status • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Portage Biotech Hosting Key Opinion Leader Webinar on How iNKT Agonists Could Improve Immuno-Oncology Treatment (GlobeNewswire) - "Portage Biotech Inc...today announced that it will host a key opinion leader (KOL) webinar on the role iNKT cells play in anticancer immune response and how iNKT targeting can be leveraged to expand the immuno-oncology landscape, Thursday, November 18, 2021, at 10a.m. Eastern Time....Dr. Kronenberg will provide an overview on invariant natural killer T cell (iNKT) cells and their mechanism of action to enable multiple parts of the immune system to attack and kill cancer."

Clinical • Oncology

Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year (GlobeNewswire) - "PORT-2: The first patient was dosed in the IMP-MEL randomized Phase 1/2 study of PORT-2, a liposomal formulation of Portage’s IMM60 iNKT agonist...The PORT-2 study has 6 arms and is expected to enroll up to 100 patients; PORT-3: The Phase 1 portion of the trial is expected to enroll 15 patients while the randomized Phase 2 portion is expected to enroll an additional 42 patients."

Trial status • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Portage Biotech Highlights First Patient Dosed in PRECIOUS-01 Study of PORT-3 for the Treatment of NY-ESO-1 Positive Solid Tumors (SeekingAlpha) - "Portage Biotech Inc...announced that the first patient has been dosed in the Phase 1 portion of the PRECIOUS-01 open-label, dose-escalation and expansion clinical trial assessing the safety, tolerability, efficacy and dosing of PORT-3 in the treatment of cancer....The phase 1 part of the trial is expected to enroll 15 patients."

Trial status • Oncology • Solid Tumor